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Tumor suppressorNuclear factor of activated T cells (NFAT) was described as an activation and differentiation factor in T cells.
NFAT1 protein is expressed in several cell types and has been implicated in the control of the cell cycle, death
and migration. Overexpression or activation of NFAT1 has been demonstrated to induce cell death in different
cell types, such as T lymphocytes, Burkitt's lymphoma, and ﬁbroblasts. Although these ﬁndings indicate a role
for NFAT1 transcription factor in control of cell death, the precise mechanisms involved in this process regulated
by NFAT1 are still poorly understood. The Ras/Raf/MEK/ERK pathway is activated by many growth factors and
cytokines that are important in driving proliferation and preventing apoptosis and is widely implicated in cell
transformation and cancer development. We show that NFAT1 protein can cooperate with Ras/Raf/MEK/ERK,
but not with the JNK, p38 or NFκB pathways in cell death induction. NFAT1 can induce a cell death pathway con-
sistent with apoptosis, which can be shifted to programmed necrosis by caspase inhibitors. Finally, through
screening genes involved in cell death regulation, although we determined that TNF-α, TRAIL and PAK7 genes
were up-regulated, only TNF-α expression was responsible for cell death in this context. These data suggest
that NFAT1 protein activation can shift oncogenic Ras/Raf/MEK/ERK signaling to acting as a tumor suppressor
pathway. These data support a potential role for regulating NFAT1 expression in gene therapy in tumors that dis-
play an activated Ras pathway, which could lead to more speciﬁc, target-directed TNF-α expression and, thus,
tumor suppression.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The nuclear factor of activated T cells (NFAT) family of transcrip-
tion factors includes four closely related proteins, designated
NFAT1-4, that are regulated by the Ca2+/calcineurin pathway [1,2].
NFAT proteins have been shown to regulate the expression of a
wide range of genes involved in immune system responses and verte-
brate development and have more recently been implicated in cancer
development [1,3,4]. An increase in intracellular calcium activates
calcineurin, a calcium/calmodulin-dependent serine/threonine phos-
phatase, which directly dephosphorylates the NFAT regulatory do-
main, allowing NFAT to translocate to the nucleus and increasing its
DNA afﬁnity [5]. The immunosuppressive drugs cyclosporin A (CsA)
and FK506, which are well-known inhibitors of calcineurin, inhibit
NFAT activity by blocking its dephosphorylation [6]. Once located in
the nucleus, NFAT proteins can bind to their target promoter ele-
ments and activate the transcription of speciﬁc responsive genes, ei-
ther alone or in combination with other nuclear partners [2]. One of
the main partners of NFAT activity is the synthesis and activation ofr, Instituto Nacional de Câncer
20231-050, Brazil. Tel.:+5521
l rights reserved.the Fos and c-Jun proteins, which are components of the AP-1 family
of transcription factors that can be activated by phorbol 12-muristate
13-acetate (PMA) [7].
NFAT1 is the prevalent NFAT isoform expressed in peripheral T lym-
phocytes. Upon T cell receptor stimulation, NFAT induces changes in the
expression of a number of cytokine genes, including IL-2, IL-3, IL-4, IL-5
and IFN-γ. However, NFAT also regulates other responsive genes, such
as c-myc, p21Waf1, CD40 ligand, FasL, CDK4 and Nur77, indicating that
these transcription factors may also be involved in the control of the
cell cycle and apoptosis [8–10]. Indeed, three-month-old NFAT1 deﬁ-
cient (NFAT1−/−) mice develop a lymphocyte hyperproliferative phe-
notype, reﬂected by a slight size increase in peripheral lymphoid
organs, accompanied by a reduction in cell death and an increased cell
cycle rate [11–14]. NFAT1−/− mice also exhibit neoplastic transforma-
tion of cartilage cells, which resemble chondrosarcomas and display
an increased propensity for chemical carcinogen-induced tumor forma-
tion [15,16].
The phenotype of NFAT1-deﬁcient mice suggests that this family
of transcription factors is likely to play a much broader role in the reg-
ulation of cell death than previously described and might be involved
in tumorigenesis. Overexpression or activation of NFAT1 protein has
been demonstrated to induce cell death in different cell types, such
as T lymphocytes, Burkitt's lymphomas, and ﬁbroblasts [16–20]. Re-
cently, our group demonstrated that NFAT1 protein can induce cell
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and can act as a tumor suppressor gene that reduces tumor formation
in mice [16]. Although these data propose a role for the NFAT1 tran-
scription factor in the control of cell death, the precise genetic mech-
anisms involved in this process regulated by NFAT1 are still poorly
described.
The Ras/Raf/MEK/ERK pathway is activated by many growth fac-
tors and cytokines that are important in driving proliferation and
preventing apoptosis [21–23]. This signaling pathway is found to be
mutationally activated or overexpressed in several human cancers,
such as melanomas, colorectal, pancreatic, papillary-thyroid and se-
rous ovarian carcinomas and lung cancers [24–28]. Furthermore,
studies using genetic or pharmacologic approaches have shown that
MEK (MAPK/ERK kinase) and ERK (extracellular signal-regulated ki-
nase) protein activities are required for the transforming activities
of Ras [29], thus supporting an oncogenic role for this pathway.
In this study, we aimed to determine the signaling pathways that
can cooperate with NFAT1, themechanism of cell death, and the critical
genes that are regulated by NFAT1 protein in the induction of cell death.
We show that the activation of NFAT1 can induce cell death in NIH3T3
ﬁbroblasts only in cooperation with the oncogenic Ras pathway. Fur-
thermore, NFAT1 cooperates with the Ras/Raf/MEK/ERK pathway in
the induction of cell death, but not with other pathways downstream
of Ras, such as the JNK (c-JunN-terminal kinase) or p38 kinase pathway.
NFAT1 induces a cell death phenotype characterized as apoptosis that
can be shifted to programmed necrosis in the presence of caspase inhib-
itors. Finally, a PCR array analysis of genes involved in apoptosis showed
that TNF-α (tumor necrosis factor alpha) presented the most abundant
mRNA up-regulation in response to NFAT1 activation, leading to mas-
sive TNF-α protein production that was directly implicated in the in-
duction of cell death. Collectively, these data suggest that NFAT1
protein can induce cell death through the regulation of TNF-α expres-
sion and that this phenotype is dependent on the activation of the
Ras/Raf/MEK/ERK pathway.
2. Experimental procedures
2.1. Cell culture and reagents
NIH3T3 cell culturesweremaintained in Dulbecco'smodiﬁed Eagle's
medium (DMEM) supplemented with 10% fetal bovine serum (FBS).
Cells were cultured in a humidiﬁed environment containing 5% CO2 at
37 °C. Inhibitors of p38 kinase (SB-203580), MEK1/2 (U0126 and
PD98059) and JNK (SP600125) were all purchased from ENZO Life
Science, while 4-hydroxytamoxifen (OHT) was obtained from
Invitrogen. Phorbol 12-muristate 13-acetate (PMA) was obtained
from Calbiochem. Recombinant mouse TNF-α (T7539) was acquired
from Sigma. Phycoerythrin-conjugated Annexin-V, 7-AAD, and Ac-
DEVD-AFCwere obtained fromBDBiosciences. Pan and Caspase-3 inhib-
itors (Z-VAD-FMK and Z-DEVD-FMK respectively), and necrostatin-1
were obtained from R&D Systems. The NFAT1 polyclonal antibody
anti-67.1 was a gift from Dr. Anjana Rao [30]. GAPDH (6C5) and
pan-Ras (sc-32) were obtained from Santa Cruz Biotechnology; total-
(#9102) and phospho-ERK1/2 (#9106) were obtained from Cell Signal-
ing, and a TNF-α neutralizing antibody (MCA1488XZ) was obtained
from AbD Serotec.
2.2. Plasmid constructs
CA-NFAT1murine cDNAhas previously been described [31] andwas
a gift from Dr. Anjana Rao. The plasmid pLIRES-EGFP-CA-NFAT1 was
constructed by subcloning CA-NFAT1 cDNA into the pLIRES-EGFP back-
bone retroviral plasmid [32]. To construct a plasmid containing NFAT1
protein responsive to the synthetic steroid 4-hydroxytamoxifen
(OHT), designated pLIRES-EGFP-CA-NFAT1-ER, a Sal1 restriction site
was introduced immediately after the CA-NFAT1 C-terminus at theoriginal stop codon using theGeneTailor Site-DirectedMutagenesis sys-
tem (Invitrogen). The original CA-NFAT1 construct contains an SV40
nuclear localization signal (NLS) at its C-terminus adjacent to its stop
codon; in pLIRES-EGFP-CA-NFAT1-ER, the NLS was excluded. The
N-terminally truncated G525R estrogen receptor responsive to tamoxi-
fen (ER™) was PCR ampliﬁed from pBabe-c-mycER™, a gift from
Dr. Gerard Evan, and subcloned at the Sal1 site to create pLIRES-EGFP-
CA-NFAT1-ER [33]. The retroviral plasmids pBabe-H-rasV12, pBabe-
IκBα-mut (Addgene plasmid 15291) and pBabe-MEK1DD (Addgene
plasmid 15268) were described previously [34,35] and were a gift
from Dr. Scott Lowe or acquired from Addgene. The luciferase reporter
construct 3×NFAT-Luc (pGL4.30; Promega), which contains three cop-
ies of the distal NFAT-AP1 site of the IL-2 promoter [36], and 6×NFκB,
containing six copies of the NFκB responsive element [37], were
constructed as described previously. All constructs were conﬁrmed by
restriction enzyme mapping and DNA sequencing.
2.3. Production of recombinant retroviruses and infection of NIH3T3 cells
The BD EcoPack2 ecotropic packaging cell line (BD-Biosciences)
was transiently transfected with a retroviral vector via calcium phos-
phate precipitation for 24 h. Cell-free virus-containing supernatant
was collected 48 h after transfection, mixed 1:1 with fresh medium,
supplemented with 8 μg/ml polybrene (FLUKA Chemie, Buchs,
Switzerland), and immediately used for spin-infection (2 × 45 min
at 420 g, room temperature) of 2.5 × 104 NIH3T3 cells. Infected
cells were incubated at 37 °C for an additional 24 h, trypsinized,
and used as indicated. To ensure reproducibility, each experiment
was repeated using cells derived from independent viral infections.
2.4. NIH3T3 cells expressing CA-NFAT1-ER, H-rasV12, MEK1DD and IκBα-mut
construction
NIH3T3-CA-NFAT1-ER or -Empty-Vector cells were generated by
transducing NIH3T3 wild-type cells with the pLIRES-EGFP-CA-
NFAT1-ER retroviral vector or Empty Vector following selection for
G418 (Invitrogen) resistance (1000 μg/ml) for 14 days. NIH3T3-CA-
NFAT1-ER cells expressing H-rasV12, MEK1DD or IκBα-mut were
generated by transducing the cells with the pBabe-H-rasV12, -MEK1DD
or -IκBα-mut retroviral vector following selection for puromycin
(Sigma) resistance (15 μg/ml) for at least 5 days.
2.5. Cell proliferation studies
NIH3T3-Empty-Vector or -CA-NFAT1-ER cells infectedwithH-rasV12
when indicatedwere plated in triplicate into 96-well microtiter plates at
a density of 8 × 103 cells per well and treated with 100 nM OHT and
20 nM PMA. When indicated, the cells were pre-treated with U0126
2 hprior toOHT addition. Cell proliferationwas analyzed at the indicated
times by a Crystal Violet assay, which involves ﬁxing the cells with etha-
nol for 10 min, followed by stainingwith 0.05% Crystal Violet in 20% eth-
anol for 10 min and solubilization withmethanol. The plate was read on
a spectrometer at 595 nm.
2.6. Sub-G0 and cell permeabilization analyses
Twelve microtiter plates were inoculated with 1 × 105 cells and
treated with OHT (100 nM) and PMA (20 nM) or with mouse recom-
binant TNF-α as indicated. When indicated, the cells were treated
with SB-203580 (1 to 80 μM), U0126 (1–80 μM), SP600125 (20–
100 μM), Z-VAD-FMK (20 μM), necrostatin-1 (20 μM) or the TNF-α
neutralizing antibody (0.5 to 4 μg/ml) 2 h prior to OHT or TNF-α
addition. On the indicated day, the cells were trypsinized, and the
supernatant was collected and washed once with phosphate-
buffered saline (PBS). Cells were then stained with propidium iodide
(75 μM) in the presence of NP-40 for Sub-G0 analysis, or with saline
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Analyses of DNA content and PI-positive cells were conducted by
collecting 20,000 events using a FACScalibur ﬂow cytometer and
CELLQuest software (BD Biosciences).2.7. Annexin-V staining
NIH3T3-CA-NFAT1-ER cells were plated at a density of 1.5 ×
106 cells/10 cm dish and treated with OHT (100 nM) and PMA
(20 nM) when indicated. At different time-points, the cells were
trypsinized, and the supernatant was collected, washed with PBS,
stained with Annexin V-PE and 7-AAD, and analyzed by ﬂow
cytometry.2.8. Transactivation assay
NIH3T3-CA-NFAT1-ER cells infected with pBabe-Empty or pBabe-
IκBα-mut when indicated were plated at 2.5 × 105 cells/10 cm dish.
After 24 h, the cells were cotransfected via calcium phosphate precip-
itation with the 3×NFAT-Luc (10 μg) or the 6xNFκB-Luc (10 μg) re-
porter plasmid and a Renilla luciferase expression plasmid (pRL-TK)
for normalization (1 μg). After 24 h, the cells were trypsinized, and
1 × 105 cells were plated in a 24-well plate, followed by the addition
of OHT (100 nM) or PMA (20 nM) 2 h later. At the indicated times,
cells were harvested and lysed with 40 μl of lysis reagent (Promega).
Crude extracts were analyzed in a Veritas microplate luminometer
(Turner Biosystems) using a dual-luciferase reporter assay system
(Promega) as directed by the manufacturer. The ﬁreﬂy luciferase re-
porter gene was normalized with the Renilla vector pRL-TK. Luciferase
activities were expressed as relative light units (RLU).2.9. Western blotting
NIH3T3 cells infected with Empty Vector or NFAT1WT, CA-NFAT1,
CA-NFAT1-ER, H-rasV12 or MEK1DD were treated when indicated
with OHT (100 nM), PMA (20 nM) or U0126 (1–20 μM). Total pro-
tein was obtained from 3.5 × 105 cells by cell lysis in buffer
containing 40 mM Tris pH 7.5, 60 mM sodium pyrophosphate,
10 mM EDTA, and 5% SDS, followed by incubation at 100 °C for
15 min. Total cell lysates were resolved via SDS-PAGE, and the pro-
teins were transferred to a nitrocellulose membrane. Antibodies
against pan-Ras, NFAT1, total- and phospho-ERK, and GAPD were
used as indicated in the Cell culture and reagents section and in the
ﬁgure legends. Immunodetection was performed with an ECL West-
ern blotting detection kit (GE Healthcare).2.10. NFAT immunolocalization and pyknotic nuclei analyses
NIH3T3-CA-NFAT1-ER cells were treated with OHT (100 nM) and
PMA (20 nM) when indicated and ﬁxed in 4% paraformaldehyde at
room temperature for 15 min. The cells were permeabilized, and
nonspeciﬁc sites were blocked with 1× PBS containing 0.5% NP-40
and 5% FBS in several 5 min washes. For NFAT1 immunolocalization,
cells were incubated for 1 h at room temperature with an NFAT1 poly-
clonal antibody in 1× PBS containing 0.5% NP-40 and 5% FBS. Then, the
cells were washed again prior to incubation with rhodamine-labeled
anti-rabbit IgG (KPL) for 30 min. For nuclear staining and to examine
the formation of pyknotic nuclei, the cells were incubated with DAPI
(300 nM) for 1 min. The cells were viewedunder anOlympus FluoView
FV10i confocal ﬂuorescence microscope. NFAT1 subcellular localization
was quantiﬁed by counting at least 100 randomly chosen DAPI stained
cells and determination of NFAT1 localization.2.11. ELISA against TNF-α
NIH3T3-CA-NFAT1-ER cells or cells expressing Empty Vector,
H-rasV12 or MEK1DD were treated with OHT (100 nM) and PMA
(20 nM) as indicated. When indicated, cells were treated with
U0126 (20 μM) 2 h prior to OHT and PMA. At different time-points,
cell-free supernatant was assessed for TNF-α protein levels using
the Murine TNF-α ELISA Development kit (PeproTech) according to
the manufacturer's instructions.
2.12. Enzymatic assay for caspase-3 activity
Caspase-3 activity was measured using the ﬂuorogenic enzyme
substrate Ac-DEVD-AFC. Cells were plated (1.5 × 106 cells/10 cm
plate) and treated with OHT (100 nM) and PMA (20 nM) as indicat-
ed. After 24 h, the cells were collected as a pellet and resuspended
in 50 μl of cell lysis buffer, then incubated on ice for 30 min. The
cells were then centrifuged at 3000 g for 5 min, and the supernatant
was transferred to a 96-well plate, to which 50 μl of reaction buffer
(20 mM PIPES, pH 7.4, 1 mM EDTA, 0.1% CHAPS, 10% Sucrose,
10 mM DTT, 100 mM NaCl2) containing 10 μg/ml of the substrate
was added. As a control, the caspase-3 inhibitor Ac-DEVD-FMK
(10 μg/ml) was added when indicated. The plate was incubated at
37 °C for 1 h, and the samples were read in a ﬂuorometer equipped
with a 400 nm excitation ﬁlter and a 505 nm emission ﬁlter or in a
spectrum with emissions varying between 480 and 520 nm. The pro-
tein content was measured using Bradford Folin's reagent method
(Bio-Rad Laboratories) and used to normalize enzyme activity,
which was expressed as a % relative to cells treated with PMA alone.
2.13. Real-time reverse transcriptase (SYBR Green) SuperArray assay
NIH3T3-CA-NFAT1-ER cells were treated with OHT (100 nM) and
PMA (20 nM) as indicated for 24 h, and total mRNA was isolated from
cells using RNeasy Mini Spin Columns (Qiagen), according to the
manufacturer's protocol. The purity and quantity of total RNAwere deter-
mined using a Nanodrop UV–visible spectrophotometer (Nano-Drop
Technologies), and RNA integrity was assessed based on the 28S and
18S ribosomal mRNA bands via agarose gel electrophoresis. First-strand
DNAwas synthesized using theRT2 First Strand kit (SABiosciences Corpo-
ration) as recommended by the manufacturer. Real-time polymerase
chain reaction (RT-PCR) was performed using STBR Green PCR Master
Mix (SABiosciences) in a 7500 Fast Real-Time PCR System (Applied Bio-
sciences) according to the manufacturer's instructions. The quality of
the primers was tested via the analysis of the melting curve. We used
the PAMM-012 Mouse Apoptosis Pathway RT Proﬁler PCR array
(SABiosciences), which proﬁles the expression of 84 genes involved in
apoptosis-related signaling.
3. Results
3.1. Both NFAT1 activation and PMA stimulation are required for the
induction of cell death in ﬁbroblasts
Although several recent studies suggest that NFAT1 protein can
induce cell death when overexpressed or activated in different cell
types, the precise cell death machinery involved in this process is still
notwell characterized [16–20]. To address this question,we constructed
a conditional NFAT1 protein responsive to the synthetic steroid
4-hydroxytamoxifen (OHT) by fusing the previously characterized con-
stitutively active NFAT1 protein (CA-NFAT1) [16,31] to theN-terminally
truncated G525R estrogen receptor (ER™), which is only responsive to
OHT (CA-NFAT1-ER; Fig. 1A) [33]. CA-NFAT1-ER cDNA was cloned into
the retroviral vector pLIRES-EGFP, which was then used to transduce
NIH3T3 cells, and these cells were subsequently stabilized via antibiotic
resistance (NIH3T3-CA-NFAT1-ER cells). The use of a conditioned
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tivation and, thus, a more detailed analysis of [1] the pathways that can
cooperate with NFAT [2], the gene expression proﬁle mediated by this
factor [3], and cell death kinetics. Furthermore, this construct bypasses
the need for a Ca2+ inﬂux to activate NFAT1 protein and therefore al-
lows the reduction of the background generated by the induction of
other Ca2+-responsive transcription factors, such as CREB and MEF2
[38–40]. Subsequent expression analysis in NIH3T3-CA-NFAT1-ER cells
of the encoded CA-NFAT1-ER construct demonstrated that the protein
functioned properly and exhibited all of the expected characteristics.
The CA-NFAT1-ER protein presented the expected apparent molecular
weight compared to wild-type or constitutively active NFAT1 protein
(Fig. 1B), was restricted to the cytoplasm (>95% of total cells) and
completely translocated to the nucleus (>95% of total cells) when treat-
ed with OHT (Fig. 1C), and showed the ability to transactivate an
NFAT-responsive reporter luciferase construct (pGL4.30) in a time-
dependent manner, reaching a plateau in 24 h, only in the presence of
OHT (Fig. 1D).
Next, we analyzed the role of the NFAT1 protein in the control of cell
proliferation and death (Fig. 2). The growth capacity of NIH3T3 cells ex-
pressing CA-NFAT1-ER was assessed in a proliferation kinetics assay, ac-
companied by crystal violet incorporation, which correlates with total
cell numbers, while cell death kinetics were accompanied by sub-G0
DNA content, which is indicative of cells undergoing apoptosis. There
was no difference between empty vector- and CA-NFAT1-ER-expressing
cells in their proliferation (Fig. 2A) and apoptosis proﬁles (Fig. 2B), with
the activation of the CA-NFAT1-ER protein observed only following OHT
application. However, the addition of the phorbol 12-muristate 13-
acetate (PMA) induced a strong decrease in cell accumulation rate
(Fig. 2C) accompanied by cell death (Fig. 2D) only in cells expressing
and showing activated CA-NFAT1-ER following treatment with OHT.
The proﬁle of cells undergoing cell death exhibiting a sub-G0DNAcontentFig. 1. Construction and validation of 4-hydroxytamoxifen responsive NFAT1 protein (CA-N
and schematic conventions: serine to alanine CA-NFAT1 mutations (yellow circles), DNA-bin
NFAT homology region (NHR, gray bars), nuclear localization signal from the SV40 virus (NLS
Identical shading patterns represent identical sequences. CA-NFAT1-ER was constructed by
truncated estrogen receptor responsive to 4-hydroxytamoxifen (OHT), as described. B)
retrovirally transduced with the indicated construct. GAPDH levels were used as a loading
in NIH3T3-CA-NFAT1-ER cells was determined by ﬂuorescence microscopy in the presenc
and visualized by ﬂuorescence and phase contrast microscopy. D) NFAT transactivation assa
and pRL-TK (Renilla normalization vector). After 24 h, they were treated with OHT (100 nM
and was expressed as light units relative to the ﬁrst time point in cells without OHT. All recan be further visualized from the results of the two representative ﬂow
cytometric analysis (Fig. 2E and F). Furthermore, NIH3T3 cells showing
activated CA-NFAT1-ER in the presence of PMA displayed time-
dependent cell death induction, culminating with massive cell death at
72 h after NFAT1 activation (Fig. 2D). Altogether, these data demonstrate
that while OHT and PMA do not alter proliferation and death in empty
vector-expressing cells, they do induce a strong cell death phenotype in
NIH3T3-CA-NFAT1-ER cells, supporting the idea that cell death is caused
by NFAT1 activation and that it depends on cooperation with a pathway
activated downstream of PMA.3.2. NFAT1 cooperates with the oncogenic Ras/Raf/MEK/ERK pathway in
the induction of cell death, but not with the NFκB pathway
To further investigate the pathways that can cooperate with NFAT1
in the induction of cell death, we analyzed the two main downstream
PMA-activated pathways: the NFkB and Ras/MAPK (mitogen-activated
protein kinase) pathways. To examine whether the NFκB transcription
factor can cooperate with NFAT1 in the induction of cell death in ﬁbro-
blasts, NIH3T3-CA-NFAT1-ER cells were transducedwith an empty vec-
tor or with a plasmid encoding a dominant-negative mutated IκBα
(IκBα-Mut) protein [35]. As expected, NIH3T3-CA-NFAT1-ER cells
carrying the empty vector underwent cell death 72 h after treatment
with OHT and PMA (Fig. 3A). However, the inhibition of NFκB activation
via overexpression of IκBα-Mut did not prevent the induction of cell
death by NFAT1 activation in cells treated with OHT and PMA
(Fig. 3A). The dominant-negative IκBα protein was functioning proper-
ly, as it was able to completely block PMA induction of NFκB
transactivation of an NFκB-responsive luciferase promoter (Fig. 3B).
These data support the idea that the NFκB signaling pathway is not
essential for NFAT1 induction of cell death.FAT1-ER). A) Schematic alignment of the NFAT1 protein and constructs. Abbreviations
ding domain (DBD, dark bars), C-terminal transactivation domains (TAD-C, blue bars),
-SV40, red bar) and N-terminally truncated G525R estrogen receptor (ER™, green bar).
deleting the NLS-SV40 signal from the CA-NFAT1 protein, followed by fusion with the
NFAT1 protein expression determined by western blotting analysis of NIH3T3 cells
control. Non-transduced cells (ND). C) The subcellular localization of NFAT1 protein
e of 0 or 100 nM OHT for 24 h. Cells were stained with DAPI and anti-NFAT1-PE Abs.
y. NIH3T3-CA-NFAT1-ER cells were transfected with pGL4.30 (NFAT responsive vector)
) when indicated. Luciferase activity was measured as described at the speciﬁed times
sults are representative of at least 3 independent experiments.
Fig. 2. NFAT1 induces cell death and reduces proliferation only in cooperation with a PMA-activated pathway. NIH3T3-Empty-Vector or -CA-NFAT1-ER cells were plated and ana-
lyzed for cell growth and death as indicated below. A and C) Analysis of proliferation kinetics based on Crystal Violet staining. Cells were plated in the absence (A) or presence (C) of
20 nM phorbol 12-muristate 13-acetate (PMA) and in the presence of OHT (100 nM) when speciﬁed. The results are representative of at least 3 independent experiments. B and D)
Cell death analysis based on the formation of subdiploid nuclei (Sub-G0). Cells were plated in the absence (B) or presence (D) of 20 nM PMA and in the presence of OHT (100 nM)
when indicated. Cells were stained with PI and analyzed by ﬂow cytometry to determine their DNA content at the speciﬁed time. SD values indicate the variance of at least three
independent experiments. E) Representative Sub-G0 cell death analysis histograms from NIH3T3-CA-NFAT1-ER cells treated with PMA (20 nM) (left panel) and OHT (100 nM)
(right panel) for 72 h, extracted from Fig. 2D. The percentage of cell death (Sub-G0) is indicated.
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pathway directly through the activation of RasGRPs (Ras guanyl
nucleotide-releasing proteins) or indirectly through the activation of
PKC protein [41,42]. To investigatewhether the Ras/MAPK pathway is in-
volved in the induction of cell death by NFAT1, NIH3T3-CA-NFAT1-
ER-expressing cells were transducedwith an empty vector orwith a plas-
mid encoding the constitutively active H-rasV12 protein. H-ras protein
expression was analyzed by western blotting to conﬁrm the over-
expression of this oncogene (Fig. 3C). As expected, only low levels of
cell death were visualized when assessed at an early time point, 48 hafter treatment with OHT and PMA, in the NIH3T3-CA-NFAT1-ER plus
empty-vector-expressing cells (Fig. 3D). However, the activation of
NFAT1 protein by OHT treatment in NIH3T3-CA-NFAT1-ER cells express-
ing the H-rasV12 oncogene was sufﬁcient to induce massive cell death at
this time point (Fig. 3D; OHT). These data suggest that H-rasV12 expres-
sion can induce cell death in cooperation with NFAT1 at an earlier time
point (48 h) when compared to cells treated only with OHT and PMA
(72 h; Fig. 2D). The H-rasV12 overexpression may accelerate the cell
death induced by NFAT1 when compared with PMA stimulation. In fact,
this phenotype can be readily visualized at cell proliferation analysis
Fig. 3. The H-ras, but not the NFκB pathway cooperates with the induction of cell death by NFAT1. A and D) Cell death analysis based on the formation of subdiploid nuclei (Sub-G0).
NIH3T3-CA-NFAT1-ER cells were transduced with the indicated vector (pBabe-Empty; -IkBα-mut or -H-rasV12) as described. Cells were plated, treated with OHT (100 nM) and
PMA (20 nM) as speciﬁed and cultured for 72 h (A) or 48 h (D). Cells were stained with PI and analyzed by ﬂow cytometry for DNA content. B) NFκB transactivation assay.
NIH3T3-CA-NFAT1-ER-expressing cells were transduced with the Empty or IκBα-mut construct as described. Then, the cells were transfected with pGL3-6×NFκB (NFκB responsive
vector) and pRL-TK (Renilla normalization vector). On the next day, the cells were treated with PMA (20 nM) for 6 h. Luciferase activity was measured as described and was
expressed as relative light units (RLU) compared to the ﬁrst graphic column. SD values indicate the variance of three independent experiments. C) H-rasV12 protein expression.
Western blotting analysis of NIH3T3 cells retrovirally transduced with the indicated plasmids for H-ras protein expression. GAPDH levels were used as a loading control. The results
are representative of at least 3 independent experiments. US. denotes unstimulated cells in all experiments.
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result in a cooperative effect to further increase cell death in cells express-
ing H-rasV12 treated with OHT (Fig. 3D; OHT + PMA). Altogether, these
data demonstrate that H-rasV12 overexpression is sufﬁcient to bypass the
need for PMA in the induction of cell death by NFAT1, supporting the idea
that NFAT1 can cooperate with pathways downstream of Ras/MAPK.
Activation of Ras protein through the induction of a phosphorylation
cascade involving several downstream MAPKKK pathways culminates
the induction of three main families of MAPKs, ERK1/2, JNK1/2/3, and
p38α/β/γ/δ kinases [29,43]. However, the JNK and p38 pathways ap-
pear not to be involved in the induction of cell death by NFAT1 because
the use of JNK- and p38-speciﬁc inhibitors (SP600125 and SB203580) to
produce a dose-response curve, at concentrations ranging from1 μMupto 80 μM, did not inhibit the induction of cell death by NFAT1 (Fig. 4A).
On the other hand, the Ras/Raf/MEK/ERK pathway appears to be funda-
mental for the induction of cell death by NFAT1 (Fig. 4B–H). MEK1/2 is
theMAPKK upstreamof ERK1/2, and their inhibition by the drug U0126
is used to evaluate ERK-mediated events. To examine whether the Ras/
Raf/MEK/ERK pathway is involved in the induction of cell death by
NFAT1, NIH3T3-CA-NFAT1-ER cells were transduced with H-rasV12
and treated with U0126 to obtain a dose-response curve (Fig. 4B).
MEK1/2 inhibition led to a reduction of the cell death induced by
NFAT1 activation (OHT) in a concentration-dependent manner in
which inhibition with U0126 at 5 μM was sufﬁcient to reduce total
cell death by 50% and 20 μM by approximately 90% (Fig. 4B). Inhibition
of MEK1/2 by U0126 was correlated with the reduction of ERK1/2
Fig. 4. The Ras/Raf/MEK/ERK pathway, but not p38 or JNK cooperates with the induction of cell death by NFAT1. A, B, D, F and G) Cell death analysis based on the formation of
subdiploid nuclei (Sub-G0). NIH3T3-CA-NFAT1-ER cells were transduced with the indicated vectors (pBabe-H-rasV12; MEK1-DD) as described. When speciﬁed, cells were
pre-treated with variable concentrations of SP600125 (JNK inhibitor), SB203580 (p38 inhibitor), U0126 or PD98059 (MEK1/2 inhibitors) 2 h prior to stimulation. Cells were treated
with OHT (100 nM) and PMA (20 nM) when indicated and cultured for 48 h (A, B, D and F) or 72 h (G) before being stained with PI and analyzed by ﬂow cytometry to determine
their DNA content. SD values indicate the variance of at least three independent experiments, and (*) indicates p ≤ 0.001. C and E) Western blotting analysis of the ERK1/2 phos-
phorylation state. NIH3T3-CA-NFAT1-ER cells were retrovirally transduced with the speciﬁed plasmid (pBabe-Empty; -H-rasV12 or -MEK1DD) as described. When indicated, cells
were pre-treated for 2 h with variable concentrations of U0126 prior to the addition of PMA (20 nM). The cells were harvested and analyzed as described 24 h after PMA stimu-
lation. GAPDH and total-ERK were used as loading controls. C) The two last lanes of the gel suffered an upshift that can be seen in all conditions (p-ERK; ERK-Total and GAPDH). A
nonspeciﬁc band can be seen only at the last lane of p-ERK under the low-intensity-speciﬁc p-ERK1/2 bands. H) Analysis of proliferation kinetics based on Crystal Violet staining.
NIH3T3-CA-NFAT1-ER cells were retrovirally transduced with the speciﬁed plasmid (pBabe-Empty or -H-rasV12) as described. When indicated, cells were pre-treated with U0126
(20 μM) 2 h prior to stimulation. Cells were treated with OHT (100 nM) when speciﬁed and cultured for the speciﬁed time. The results are representative of at least 3 independent
experiments. US. denotes unstimulated cells in all experiments.
2022 B.K. Robbs et al. / Biochimica et Biophysica Acta 1833 (2013) 2016–2028phosphorylation induced by H-rasV12 and by PMA stimulation
(Fig. 4C), supporting the idea that U0126 inhibition of cell deathwas oc-
curring through an ERK1/2-dependent pathway. Corroborating these
data, another MEK1/2 inhibitor, PD98059, was also able to reduce cell
death induced by NFAT1 and H-ras12 activation in a dose-response
manner (Fig. 4D). Although PD98059 is a selective inhibitor of MEK1/
2, it has approximately 100-fold less afﬁnity for MEK1/2 then does
U0126 [44]. This could explain the lower level of cell death inhibition
(30%) by PD98059 when compared to U0126 (90%; Fig. 4B and D).
To exclude the possibility that H-rasV12 could be cooperating with
NFAT1 through pathways other than Raf/MEK, and to circumvent any
possible nonspeciﬁcity of the drugs U0126 and PD98059, we used a
constitutively active MEK1 protein (MEK1DD) [35]. Transduction of
NIH3T3-CA-NFAT1-ER cells with the plasmid encoding MEK1DD led to
the phosphorylation of ERK1/2 at the same level as observed followingH-rasV12 overexpression (Fig. 4E). Furthermore, MEK1DD expression
was sufﬁcient to bypass the need for H-rasV12 expression or PMA in
the induction of cell death led by NFAT1 (Fig. 4F). Cells expressing
CA-NFAT1-ER and MEK1DD underwent cell death at levels comparable
to those in cells expressing H-rasV12, solely in response to the activa-
tion of NFAT1 by OHT. PMA stimulation did not increase the cell death
induced by NFAT1 activation and MEK1DD expression, suggesting that
the PMA-activated-pathway that cooperates with NFAT1 is, in fact, the
Ras/Raf/MEK/ERK pathway (Fig. 4F). To exclude other possible roles of
PMA-activated pathways in the induction of cell death, CA-NFAT1-
ER-expressing cells were treated with PMA and OHT, and the MEK/
ERKpathwaywas inhibited usingU0126 (Fig. 4G). As shownpreviously,
the activation of NFAT1 by OHT and stimulation by PMA strongly in-
duced cell death. However, the inhibition of the ERK1/2 pathway
completely blocked cell death in these cells (Fig. 4G).
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NIH3T3 cells is capable of inducing all the hallmarks of cell transfor-
mation including loss of contact-induced growth inhibition [16,45].
To visualize the transformation phenotype induced by H-rasV12,
NIH3T3-CA-NFAT1-ER cells were infected with the plasmid encoding
this oncogene or with an empty vector, and the proliferation kinetics
were examined (Fig. 4H). Unlike control cells, which stopped growing
once they reached conﬂuence, the H-rasV12-expressing cells over-
grew the monolayer and continued to proliferate beyond conﬂuence.
However, activation of NFAT1 by treatment with OHT in cells express-
ing CA-NFAT1-ER and H-rasV12 led to a complete repression of cell
accumulation, which resulted in a large decrease in cell numbers
(Fig. 4H). Surprisingly, unlike H-rasV12-expressing cells treated
with the inhibitor U0126, which only displayed a small reduction in
their cell proliferation proﬁle, the MEK1/2 inhibitor apparently par-
tially blocked the induction of cell death by NFAT1. However, these
cells did not overgrow the monolayer and reached the level of cells
expressing H-rasV12 in the absent of NFAT1 activation, as one might
expect. This might be explained by two possible reasons: ﬁrst, that
the inhibitor U0126 might not completely block cell death induced
by NFAT1 and H-rasV12, which is in agreement with Fig. 4B, where
it inhibits only around 90% of cell death; or second, that NFAT1 signal-
ing independent of MEK1/2 cooperation might inﬂuence cell prolifer-
ation (e.g. cell cycle entry) in conﬂuent cell culture, inhibiting the
monolayer overgrowth. In fact, we have previously shown that
NFAT1 expression can induce cell cycle arrest in cultures [16]. How-
ever further experiments are needed to investigate this phenomenon.
Altogether, these results demonstrate the need for an active Ras/Raf/
MEK/ERK pathway for cooperation with the induction of cell death by
NFAT1.
3.3. NFAT1 induces an apoptotic cell death phenotype that can be shifted
to programmed-necrosis-like cell death by caspase inhibitors
NFAT1 activation clearly induces DNA fragmentation and the ac-
cumulation of a Sub-G0 DNA content, which is an indicative of cells
undergoing apoptosis. We next asked whether NFAT1 could induce
other phenotype characteristic of cells undergoing cell death by apo-
ptosis. When NFAT1 was activated (OHT) in NIH3T3 cells in the pres-
ence of PMA, we observed increased phosphatidylserine exposition
compared to controls, as analyzed by annexin V staining (Fig. 5A).
The increase of annexin V positive cells was followed by cell perme-
abilization, as shown by 7-AAD incorporation, which is an indicative
of cells undergoing apoptosis followed by late necrosis cell membrane
destabilization (Fig. 5A). To further analyze whether NFAT protein
can induce apoptosis in NIH3T3 cells, caspase-3 activity was accessed.
NFAT1 activation in cooperation with the Ras pathway led to a
seven-fold induction of caspase-3 activity, which could be completely
blocked by caspase-3 inhibitor, DEVD-fmk (Fig. 5B). A representative
spectrum of the caspase-3 assay is shown for better visualization
(Fig. 5C). Next, we examined the morphological characteristics of
NIH3T3 cells dying under NFAT1 regulation. Accordingly, NIH3T3-
CA-NFAT1-ER cells were treated with PMA alone or in the presence
of OHT, and cellular morphology was visualized via phase contrast
microscopy, while nuclear size and DNA condensation were analyzed
by ﬂuorescence microscopy of DAPI-stained DNA. Whereas cells
treated with PMA alone displayed a normal ﬁbroblastic appearance,
made cell–cell contact and exhibited a normal nuclear size and no
pyknotic nuclei, cells with activated NFAT1 were released from cell–
cell contacts, had suffered cell shrinkage and exhibited the formation
of pyknotic nuclei at 48 h (Arrows, Fig. 5D). These phenotypes
increased at 72 h, when more cells displayed these characteristics
whenNFAT1was activated, as represented by the formation of pyknotic
nuclei observed at a lower magniﬁcation (Wide view; Fig. 5D).
To further investigate the apoptotic cell death induced by NFAT1,
we checked whether the pan-caspase inhibitor ZVAD-fmk couldabolish the cell death induced by this factor. For this purpose,
NIH3T3-CA-NFAT1-ER cells were treated with OHT to activate
NFAT1 and with PMA when indicated, and cell death was analyzed
based on a Sub-G0 DNA proﬁle and propidium iodide staining in per-
meable cells. As expected, only a very small number of cells had un-
dergone DNA fragmentation 24 h after stimulation with OHT and
PMA in the presence or absence of ZVAD-fmk (Fig. 5E; left panel).
Furthermore, ZVAD-fmk alone or in single combination with OHT or
PMA did not induce signiﬁcant cell death, demonstrating that this
caspase inhibitor is not by itself responsible for the induction of cell
death (Fig. 5E). However, surprisingly, approximately 90% of the
cells treated with OHT and PMA in the presence of ZVAD-fmk were
permeable at 24 h, as shown by propidium iodide staining (Fig, 5E;
right panel). The incorporation of propidium iodide was not through
passive incorporation and reﬂected cell death since control cells did
not stain for PI and all cells from ZVAD-fmk treated wells in the pres-
ence of OHT and PMA were loose and did not re-adhere to plate after
treatment removal (data not shown). Because almost all of the cells
treated with OHT and PMA had died in the presence of ZVAD-fmk at
24 h but lacked DNA fragmentation, we assumed that this outcome
might not be due to apoptosis but ZVAD-fmk might have shifted to
another cell death modality as programmed necrosis. One of the
best-studied and fundamental biochemical pathways involved in
programmed necrosis is regulated by RIP1 kinase, and the inhibition
of this kinase by necrostatin-1 can block this cell death modality
[46]. As shown in Fig. 5E, the addition of necrostatin-1 completely
blocked cell death induced by OHT and PMA in the presence of
ZVAD-fmk, supporting the idea that NFAT1 can induce apoptotic cell
death which can be shifted most likely to programmed necrosis by
caspase inhibitors (Fig. 5E; right panel).
3.4. TNF-α expression regulated by NFAT1 and the Ras/MAPK pathway is
responsible for the induction of cell death
To determine which gene involved in cell death regulation is being
induced by NFAT1 in cooperation with the Ras/MAPK pathway, we
performed a screening of apoptosis-related genes using a real-time
PCR assay (RT2 Proﬁler PCR array). mRNA from NIH3T3-CA-NFAT1-
ER-expressing cells was isolated 24 h after stimulation with PMA
alone or in the presence of OHT, since 24 h is the NFAT1
transactivation peak and there is no apparent cell death at that
time. NFAT1 activation, in cooperation with PMA, led to a 5656-fold
up-regulation of TNF-α mRNA levels and more discrete increases in
TRAF-1 (223 fold), TRAIL (47 fold), Pak-7 (25 fold) and Fas receptor
(7 fold) (Fig. 6A). The expression of the other 79 genes showed
changes of less than 2 fold, which is a good indication that the exper-
iment was conducted correctly and that NFAT1 actually only regu-
lates the mentioned genes in this model. Because TNF-α was the
most up-regulated gene and is a direct inducer of cell death through
apoptosis, we next analyzed protein production for this cytokine.
NIH3T3-CA-NFAT1-ER-expressing cells were stimulated by OHT
and/or PMA or left unstimulated, and TNF-α accumulation was ana-
lyzed by ELISA (Fig. 6B). While stimulation with OHT or PMA alone
did not induce TNF-α production at any time point checked, activa-
tion of NFAT1 and the Ras/MAPK pathway by PMA led to the accumu-
lation of TNF-α at 24 h after stimulation, with a production peak at
48 h (Fig. 6B), which correlates with the cell death data shown
above. TNF-α production is completely dependent on the activation
of both NFAT1 and the Ras/Raf/MEK/ERK pathway as demonstrated
in Fig. 6C. While TNF-α production induced by NFAT1 (OHT) was
completely dependent on the PMA activated pathway, it could be re-
capitulated by H-rasV12 or MEK1DD but not by Empty Vector expres-
sion (Fig. 6C), suggesting that Ras/Raf/MEK/ERK pathway is sufﬁcient
to cooperate with NFAT1 to the production of TNF-α. Furthermore,
the inhibition of MEK1/2 by U0126 completely abolished TNF-α pro-
duction induced by NFAT1 in cooperation with PMA or H-rasV12,
Fig. 5. NFAT1 induces an apoptotic cell death phenotype that can be shifted to programmed-necrosis-like cell death by caspase inhibitors. NIH3T3-CA-NFAT1-ER cells were used for
all experiments. A) Apoptotic cell death accompanied by phosphatidylserine exposition. Cells were plated and treated with PMA (20 nM) and OHT (100 nM) when indicated. At the
speciﬁed time, cells were harvested and stained with Annexin-V and 7-AAD. Cells were analyzed via ﬂow cytometry to detect phosphatidylserine exposition and cell perme-
abilization. B and C) Caspase-3 activity assay. Cells were plated, treated with PMA (20 nM) and OHT (100 nM) when indicated and harvested 48 h later. Caspase-3 activity was
assessed, and as a control, the caspase-3 inhibitor DEVD-FMK was used as described. The ﬂuorescence of cell extracts was analyzed with excitation at 400 nm and emission at
505 nm (B) or by excitation at 400 nm and with a screening emission of 480 to 520 nm (C). B) Caspase-3 activity was normalized and expressed as a % relative to cells treated
only with PMA. SD values indicate the variance of at least three independent experiments, and (*) indicates p ≤ 0.001. C) Representative spectrum from (B). D) Analysis of the
formation of pyknotic nuclei and cell morphology. Cells were plated and treated 24 h later with OHT (100 nM) and PMA (20 nM) as indicated. At the speciﬁed time, cells were
stained with DAPI and analyzed by ﬂuorescence or phase contrast microscopy. Cells undergoing the formation of pyknotic nuclei (white arrows) and displaying apoptotic morphol-
ogy (black arrows) are indicated. E) Cell death analysis based on the formation of subdiploid nuclei (Sub-G0; left panel) and cell permeabilization (right panel). Cells were
pre-treated when indicated with 20 μM Pan caspase inhibitor (ZVAD-FMK) and 20 μM necrostatin-1 (Nec1) for 2 h prior to treatment with OHT (100 nM) and PMA (20 nM)
and cultured for 24 h. Cells were then stained with PI and analyzed by ﬂow cytometry for DNA content and cell permeabilization, as described. SD values indicate the variance
of at least three independent experiments.
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erate with NFAT1 for the production of TNF-α. To investigate whether
TNF-α is directly implicated in cell death induction in NIH3T3 cells,
we stimulated these cells with OHT and PMA and tested whether
TNF-α neutralization could prevent cell death. While control cells
underwent cell death as expected, pre-treatment of these cells with
the neutralizing TNF-α antibody reduced cell death in a dose-
response manner, with the maximum reduction reaching approxi-
mately 80% (Fig. 6D). These data support a direct involvement of
TNF-α accumulation in the induction of cell death in NIH3T3 cells.
However, since TNF-α, when bound to its receptor, TNFR1, can acti-
vate three main pathways, an inﬂammatory, an apoptotic or a necrot-
ic pathway, we next evaluated whether TNF-αwas directly and solely
responsible for the phenotypes induced by NFAT1. To examine
whether TNF-α is capable to induce cell death by apoptosis, NIH3T3
wild type cells were treated with recombinant mouse TNF-α to obtain
a concentration-response curve (Fig. 6E). TNF-α addition led to an
induction of the cell death in a concentration-dependent manner
leading to massive subdiploid nuclei formation accompanied by cell
permeabilization at 72 h (Fig. 6E). Furthermore, the addition of re-
combinant TNF-α to NIH3T3 cells completely recapitulated the cell
death phenotype induced by NFAT1 and PMA in the presence ofpan-caspase inhibitor, ZVAD-fmk (Figs. 5E and 6F). While TNF-α or
ZVAD-fmk alone did not induce signiﬁcant cell death at an early
time point (24 h) when evaluated by subdiploid nuclei formation or
by cell permeabilization (Fig. 6F), they promptly induced cell death
in combination (TNF-α plus ZVAD-fmk; Fig. 6F). Cells treated with
TNF-α and ZVAD-fmk displayed high level of cell permeabilization
but no signiﬁcant level of cells with DNA fragmentation, an indicative
of cells undergoing programmed necrosis (Fig. 6F). Corroborating
these data, the process of cell death was almost completely blocked
by necrostatin-1 (Fig. 6F, right panel). These data support a mecha-
nism where TNF-α can activate a primary apoptotic pathway in
NIH3T3 cells that can be shifted to a programmed necrotic pathway
when caspases are blocked. Altogether, these data support the idea
that NFAT1 activation, in cooperation with the Ras/Raf/MEK/ERK
pathway, is able to induce TNF-α production and accumulation, and
that this phenomenon is directly implicated in the induction of cell
death in NIH3T3 cells.
4. Discussion
Although the function of NFAT proteins is better characterized in
the regulation of the immune response, recent works have postulated
Fig. 6. NFAT1 induces cell death through up-regulation of TNF-α expression in cooperation with the Ras/Raf/MEK/ERK pathway. NIH3T3-CA-NFAT1-ER-expressing cells were used
for all experiments. A) SuperArray analysis of gene expression regulated by NFAT1. Cells were plated and treated with PMA (20 nM) alone (Control Sample) or PMA (20 nM) with
OHT (100 nM) (Test Sample). After 24 h, mRNA was extracted and used for real-time SuperArray analysis, as described. The fold change values are relative to the Control Sample.
Bars indicate the range of two independent experiments. B and C) Analysis of TNF-α protein levels. NIH3T3-CA-NFAT1-ER cells non-transduced (B) or transduced with Empty-,
H-rasV12- or MEK1DD-expressing vectors (C) were plated and treated with OHT (100 nM) and PMA (20 nM) as indicated, and the cell-free supernatant was assessed for TNF-α
protein levels by ELISA at the indicated time, as described, or at 48 h in Figure C. When indicated, cells were pre-treated with U0126 (20 μM) 2 h prior to stimulation. US. denotes
unstimulated cells. D and E) Cell death analyzed based on the formation of subdiploid nuclei (Sub-G0). D) NIH3T3-CA-NFAT1-ER cells were pre-treated when indicated with var-
iable amounts of a TNF-α neutralizing antibody (anti-TNF-α) for 2 h prior to treatment with OHT (100 nM) and PMA (20 nM) and cultured for 72 h. Cells were stained with PI and
analyzed by ﬂow cytometry to determine their DNA content at the speciﬁed time. E) NIH3T3 wild type cells were treated with variable amounts recombinant murine TNF-α and
cultured for 72 h. Cells were stained with PI and analyzed by ﬂow cytometry to determine their DNA content and cell permeabilization. F) Cell death analysis based on the formation
of subdiploid nuclei (Fig. 6F, left panel) and cell permeabilization (Fig. 6F, right panel). Cells were pre-treated when indicated with 20 μM Pan caspase inhibitor (ZVAD-FMK) and
20 μM necrostatin-1 (Nec1) for 2 h prior to treatment with recombinant murine TNF-α (20 ng) and cultured for 24 h. Cells were then stained with PI and analyzed by ﬂow cytom-
etry for DNA content and cell permeabilization, as described. B, C, D, E and F) SD values indicate the variance of at least three independent experiments.
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development and progression [4]. We, and others, have previously
proposed that NFAT1 can function as a tumor suppressor gene, possi-
bly through the induction of cell death in transformed cells [15,16].
However, the mechanism by which NFAT1 might exert this role is
still elusive. Here, we have shown that NFAT1 protein can induce
cell death in NIH3T3 ﬁbroblasts, in cooperation with the oncogenic
H-ras pathway (Figs. 2 and 3). It has been demonstrated that NFκB
can cooperate with NFAT in the induction of cell death in aggressive
B-cell lymphomas through the induction of B-lymphocyte stimulator
(BLyS) [47]. Despite the activation of NFκB by PMA, this pathway was
not found to cooperate in the induction of cell death by NFAT1
(Fig. 3). Furthermore, we determined that the activation of the Ras/
Raf/MEK/ERK1/2 pathway is fundamental for the induction of cell
death by NFAT1, whereas JNK and p38MAPK activation is dispensable
(Fig. 4). NFAT1 can induce a mixed mode of cell death consisting pre-
dominately of apoptotic phenotype cell death that can be shifted for a
programmed necrotic cell death pathway in the presence of caspase
inhibitors (Fig. 5). Finally, NFAT1, in cooperation with the H-ras path-
way, induces cell death through the up-regulation of TNF-α gene and
protein production, which can be almost completely abolished byneutralization of TNF-α (Fig. 6). These data support the idea that
cooperation between NFAT1 and the Ras/Raf/MEK/ERK pathway is in-
volved in the induction of cell death through TNF-α production and
possibly in tumor suppression initiated by this transcription factor.
The Ras/Raf/MEK/ERK pathway is most often associatedwith the in-
duction of cell transformation and tumor progression, being activated in
over 90% of pancreatic cancers, 66% of all melanomas and 50% of most
types of carcinoma [48]. Activated ERK1/2 phosphorylates and regulates
the activities of an ever growing roster of substrates that are estimated
to compromise over 160 proteins, including several kinases, phospha-
tases, transcription factors and cytoskeletal proteins [49]. Furthermore,
depending on the particular cell type involved, ERK signaling can regu-
late processes involved in cell transformation, such as proliferation,
differentiation, survival, migration, angiogenesis and chromatin remod-
eling [48]. However, recent works have postulated that ERK signaling
can also induce the cell death machinery directly via the up-regulation
of the pro-apoptotic proteins Bax and p53, or indirectly by sensitizing
tumor cells through the up-regulation of TRAIL death receptor 4
[50–53]. These data support a dual role for ERK signaling, which might
exert a pro- or anti-tumorigenic effect depending on the presence of
other still not well-characterized pathways. Our data support the idea
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duction of cell death and, thus, in accord with our previously published
data, possibly cooperate in the induction of a tumor suppression pheno-
type [16].
Apoptosis operates in adult organisms to maintain normal cellular
homeostasis. Violation of this cellular process can result in cancer, auto-
immunity, and other diseases. The apoptotic pathway ismorphologically
characterized by rounding-up of cells, reduction of the cellular volume,
and chromatin condensation and fragmentation, while biochemically,
it involves caspase activation, culminating in caspase-3 activation, and
exposition of phosphatidylserine [54]. As demonstrated here, NFAT1
can induce all of these characteristics in NIH3T3 ﬁbroblasts. It was previ-
ously proposed that NFAT proteins can induce apoptosis in different
models and cell types, such as in T-lymphocytes, ﬁbroblasts, and neu-
rons, though the mechanism underlying this function is still controver-
sial [16,17,55,56]. NFAT1 is highly expressed in peripheral T cells
involved in controlling the termination of the immune response by in-
ducing apoptosis. Activation-induced cell death (AICD) is a particular
form of apoptosis that is important for themaintenance of immune sys-
tem homeostasis. One important route of AICD is the activation of
so-called death receptors by their ligands, particularly, FasL, TNF-α,
and, more recently, TRAIL. Here, we show that in coordination with
ERK1/2 signaling, NFAT1 proteins can robustly up-regulate TNF-α gene
expression and, more discretely, that of the TRAIL gene, whereas no ef-
fect on FasL expression was detected, in NIH3T3 cells. Moreover,
TNF-α protein expression was associated with at least 80% of the total
cell death observed, supporting a key role for this cytokine in the induc-
tion of apoptosis in this model. NFAT1 activation also led to the
up-regulation of other genes involved in cell death, such as TRAF-1 and
the FAS receptor (Fig. 6A). Although transcriptional regulation of
TRAF-1 by NFAT1 has not been described, this up-regulation could rep-
resent indirect regulation via NFκB activation through the ligation of
TNF-α to its receptor [57]. Furthermore, although the up-regulation of
the FAS receptor through NFAT1 activation could be involved in the in-
duction of cell death in NIH3T3 cells, there was no signiﬁcant detection
of FasL mRNA that could explain this phenomenon (data not shown).
NFAT1 was apparently able to induce different cell death pathways
consisting mainly of apoptosis but with a contribution of programmed
necrotic cell death in the presence of inhibited caspases. Recent pharma-
cological and genetic evidence suggests that necrosis can occur in a
tightly regulated fashion and mediate programmed cell death, in
which signaling through RIP1 kinase appears to be essential [58]. Al-
though this hypothesis is still controversial, programmed necrosis
might have large implications in cancer development and, possibly,
treatment because several cancer cell lines are sensitive to this death
modality when treated with DNA damaging compounds or with death
receptor ligands, such as TRAIL and TNF-α [59]. Programmed necrosis
generally only occurs in cells where the apoptotic protein caspase-8 is
inhibited by a caspase inhibitor, such as Z-VAD-fmk, or in cells that
overexpress the caspase-8 inhibitor FLICE-inhibitory protein short iso-
form (FLIPs) [60]. Our data clearly show that NFAT1 can induce cell
death through programmed necrosis in the presence of Z-VAD-fmk, as
characterized by the observation of cell permeabilizationwithout nucle-
ar fragmentation and by the dependency of the activity of RIP1 kinase, as
shownusing its inhibitor necrostatin-1 (Fig. 5E). In vivo, the inhibition of
programmed necrosis by necrostatin-1 was shown to delay ischemic
brain injury in mice, inhibit myocardial cell death, and reduce infarct
size [61]. One interesting correlation is that TNF-α is one of the main
molecules involved in this pathology and that NFAT1 protein is
expressed in both the brain and myocardial cells. Altogether, these
data support a possiblemechanism throughwhichNFAT1 could regulate
the induction of cell death via apoptosis and, in the presence of inhibited
caspases as in cells that overexpress FLICE protein, could induce
programmed necrosis, contributing to further understanding the in-
volvement of this transcription factor in cancer, immune response ter-
mination and, possibly, brain and heart injuries.The regulation of TNF-α expression byNFAT1 could account for both
the apoptotic and the programmed necrotic cell death observed in
NIH3T3 cells. Ligation of TNF-α to its receptor, TNFR1, can activate
three main pathways: (1) NFκB, leading to a pro-inﬂammatory and
anti-apoptotic response; (2) caspases, leading to apoptosis; and
(3) RIP1 and RIP3, in the absence of caspase-8 activity, which leads to
necrotic cell death [61]. TNF-α transcription can be activated in the im-
mune system by a diverse group of well-described stimuli depending
on the cell type involved, such as through toll-like receptor activation
(TLR), T- and B-cell receptor antigen ligation, and stimulation by cyto-
kines such as IL-1, IFN-γ and TNF-α itself [62]. The TNF-α proximal pro-
moter displays a highly conserved region of approximately 200
nucleotides in mammals that contains biding motifs that can be recog-
nized by transcription factors activated downstream of these stimuli
[62]. Six NFATbinding sites have been identiﬁed in the TNF-α promoter,
in addition to four Ets/Elk, two Sp1, and one ATF-2/c-Jun binding sites
[62–64]. It has previously been demonstrated that NFAT signaling can
cooperate with downstream pathways activated by JNK and p38 ki-
nases in the transactivation of the TNF-α gene, possibly through the ac-
tivation of and cooperation with the ATF-2 and c-Jun transcription
factors [65–67]. Here, we have shown that in H-rasV12-transformed ﬁ-
broblasts, both the NFAT1 and ERK1/2 signaling pathways are funda-
mental for the transcriptional up-regulation of the TNF-α gene, while
JNK and p38 signaling are dispensable. Mechanistically, ERK1/2 kinases
could augment the DNA binding activity of NFAT directly by phosphor-
ylating its N- and C-termini, which would culminate in increased bind-
ing of NFAT to the TNF-α promoter and, thus, increased expression [68].
However, ERK1/2 signaling can also activate the Elk-1, SP-1, ATF-2 and
c-Jun transcription factors, which could bind to the TNF-α promoter
and cooperate with NFAT1 to induce TNF-α expression [49]. Although
our data clearly show cooperation between NFAT1 and ERK1/2 in
TNF-α gene regulation, further experiments are needed to specify
which signal downstream of ERK is responsible for this phenomenon.
While the major obstacle to the therapeutic exploitation of TNF-α
for cancer treatment is its ability to elicit a systemic inﬂammatory re-
sponse syndrome, the expression of NFAT1 proteins in tumors
exhibiting an activated Ras/Raf/MEK/ERK pathway could lead to mas-
sive local production of TNF-α and, thus, induce tumor suppression
with a lower systemic inﬂammatory effect. Furthermore, the Ras/Raf/
MEK/ERK oncogenic pathway might sensitize transformed cells to
NFAT1-induced cell death, and thus, NFAT1 could convert a well-
characterized oncogenic pathway to become a tumor suppressor path-
way. NFAT1 overexpression could be a potential mechanism to be
exploited in gene therapy for cancers that exhibit the over-activation
of the MEK/ERK pathway, leading to more-speciﬁc, targeted treatment.
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